TRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertension

IPO/OfferingPositive

AI Analysis

Summary

TRexBio priced its IPO at $116.7 million on Thursday, with backing from Eli Lilly and Nobel Prize-winning science. Retension simultaneously completed a $45 million Nasdaq debut focused on hypertension treatment.

Importance:7/10

Sentiment:

0.70

IPOcapital_raiseEli LillybiotechTregshypertension

Related Companies

$LLY

Read the original article

Published by Endpoints News on October 9, 2026 7:54 AM

Read Original